Cardiol Therapeutics (CRDL) Restructuring Costs (2020 - 2021)
Cardiol Therapeutics (CRDL) reported Restructuring Costs of $1.2 million for Q2 2021, up 125.41% on a YoY basis from $515073.0 in Q2 2020, and up 125.41% quarter-over-quarter from $515073.0 in Q2 2020.
Cardiol Therapeutics (CRDL) Restructuring Costs (2020 - 2021) Analysis & Trends
Cardiol Therapeutics has reported Restructuring Costs for 2 years, with the latest figure at $1.2 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Cardiol Therapeutics | 169.92 Mn | 149.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 1.16 Mn |
| Jun 30, 2020 | 515,073.04 |